醋酸甲羟孕酮联合化疗对子宫内膜癌术后患者的治疗效果

Therapeutic effect of medroxyprogesterone acetate combined with chemotherapy in endometrial cancer patients after surgery

目的探讨醋酸甲羟孕酮联合化疗对子宫内膜癌术后患者的治疗效果。方法根据治疗方式的不同将115例子宫内膜癌患者分为对照组(n=57)和观察组(n=58),两组患者均行子宫及双侧附件切除术,对照组患者术后予以化疗,观察组患者在对照组的基础上予以醋酸甲羟孕酮治疗。比较两组患者的临床疗效、肿瘤标志物[糖类抗原125(CA125)、人附睾蛋白4(HE4)、人类软骨糖蛋白39(YKL-40)]水平、炎症因子[肿瘤坏死因子-α(TNF-α)、白细胞介素(IL)-4、IL-8]水平及不良反应发生情况。结果观察组患者的总有效率为75.86%,明显高于对照组患者的50.88%,差异有统计学意义(P﹤0.01)。治疗后,两组患者血清CA125、HE4、YKL-40、TNF-α、IL-4及IL-8水平均低于本组治疗前,观察组患者血清CA125、HE4、YKL-40、TNF-α、IL-4及IL-8水平均低于对照组,差异均有统计学意义(P﹤0.05)。两组患者的不良反应总发生率比较,差异无统计学意义(P﹥0.05)。结论醋酸甲羟孕酮联合化疗可提高子宫内膜癌术后患者的临床疗效,降低血清肿瘤标志物水平,减轻炎症反应,且不会增加不良反应。

Objective To investigate the therapeutic effect of medroxyprogesterone acetate combined with chemotherapy in endometrial cancer patients after surgery.Method A total of 115 endometrial cancer patients were divided into control group(n=57)and observation group(n=58)according to different treatment methods.Both groups of patients underwent hysterectomy and bilateral adnexectomy.The patients in the control group were given chemotherapy after the surgery,and the patients in the observation group were treated with medroxyprogesterone acetate based on the control group.The clinical efficacy,tumor marker[carbohydrate antigen 125(CA125),human epididymis protein 4(HE4),human cartilage glycoprotein 39(YKL-40)]levels,inflammatory factor[tumor necrosis factor-α(TNF-α),interleukin(IL)-4,IL-8]levels,and the occurrence of adverse events were compared between the two groups.Result The total effective rate of the observation group was 75.86%,which was significantly higher than 50.88%of the control group,and the difference was statistically significant(P<0.01).After the treatment,the serum CA125,HE4,YKL-40,TNF-α,IL-4,and IL-8 levels in the two groups were lower than those before the treatment,and the above indicators in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).There was no statistically significant difference in the total incidence of adverse events between the two groups(P>0.05).Conclusion Medroxyprogesterone acetate combined with chemotherapy could improve the clinical efficacy of endometrial cancer patients after surgery,reduce serum tumor marker levels,and alleviate inflammatory response without increasing adverse events.